Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients

被引:96
作者
Barker, CC
Butzner, JD
Anderson, RA
Brant, R
Sauve, RS
机构
[1] Univ British Columbia, Dept Pediat, Vancouver, BC V6T 1W5, Canada
[2] Univ Calgary, Dept Pediat, Calgary, AB T2N 1N4, Canada
[3] Univ Calgary, Dept Oncol, Calgary, AB, Canada
[4] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada
关键词
hematopoietic stem cell transplantation; veno-occlusive disease; pediatric; risk factor; survival;
D O I
10.1038/sj.bmt.1704069
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
The incidence, risk factors and mortality of veno-occlusive disease (VOD) were identified for 142 pediatric hematopoietic stem cell (HSC) trans plant recipients with hematological malignancies (83), solid tumors (41) and nonmalignant diseases (18). This historical cohort of 142 HSC transplant patients, from January 1993 through June 2000, was assessed by chart review. Risk factors for the development of VOD and mortality were assessed by multiple logistic regression and Kaplan-Meier survival curves respectively. The incidence of VOD was 18.3% (26/142 transplants). Multivariate analysis reconfirmed the known pretransplant risk factors of induction therapy with busulfan and transplantation with matched unrelated donor cells as significant risk factors for the development of VOD. In addition, two new risk factors, positive CMV serology in the recipient and TPN provided in the 30 days prior to transplant, were identified. Mortality in transplant patients at 100 days was greater in the VOD-positive group (10/26 (38.5%)) compared to the VOD-negative group (11/116 (9.5%)(P = 0.001)). The risk of death was 4.97 times higher with 95% CIs (2.11, 11.71) for the VOD-positive group. Decreasing the risk factors for VOD may decrease mortality in this patient population.
引用
收藏
页码:79 / 87
页数:9
相关论文
共 42 条
[1]  
Bisogno G, 1997, MED PEDIATR ONCOL, V29, P245, DOI 10.1002/(SICI)1096-911X(199710)29:4<245::AID-MPO2>3.0.CO
[2]  
2-M
[3]   FREQUENCY OF VENOOCCLUSIVE DISEASE OF THE LIVER IN BONE-MARROW TRANSPLANTATION WITH A MODIFIED BUSULFAN CYCLOPHOSPHAMIDE PREPARATIVE REGIMEN [J].
BRODSKY, R ;
TOPOLSKY, D ;
CRILLEY, P ;
BULOVA, S ;
BRODSKY, I .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1990, 13 (03) :221-225
[4]  
BRUGIERES L, 1988, BONE MARROW TRANSPL, V3, P53
[5]  
Carreras E, 1998, BLOOD, V92, P3599
[6]   Toxic injury to hepatic sinusoids: Sinusoidal obstruction syndrome (veno-occlusive disease) [J].
DeLeve, LD ;
Shulman, HM ;
McDonald, GB .
SEMINARS IN LIVER DISEASE, 2002, 22 (01) :27-41
[7]  
ESSELL JH, 1992, BONE MARROW TRANSPL, V10, P367
[8]   Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation - A randomized, double-blind, placebo-controlled trial [J].
Essell, JH ;
Schroeder, MT ;
Harman, GS ;
Halvorson, R ;
Lew, V ;
Callander, N ;
Snyder, M ;
Lewis, SK ;
Allerton, JP ;
Thompson, JM .
ANNALS OF INTERNAL MEDICINE, 1998, 128 (12) :975-+
[9]  
Frisk P, 1998, ACTA PAEDIATR, V87, P579
[10]  
Gibbs JP, 1998, DRUG METAB DISPOS, V26, P52